ASX 200·· All Ords·· Small Ords·· Resources··
Markets
TLX A$15.85 JDS 24.7

Telix Pharmaceuticals Limited

TLX ·ASX ·Health Care ·Australia

Live price 20 min delayed
A$15.85
Mkt capA$5.37bn
P/E111.7x
Div yieldn/a
1Y return+9.9%
52-week range$8.26–$18.21
24.7
Jones Dynamic Risk Score
-6.8 since 28 Sep

Scores as at 4 October 2026. Members see this week's.

The Jones Overview

Telix Pharmaceuticals (ASX: TLX) is that rare thing in Australian biotech: a company that actually sells something. Its lead product, the prostate cancer imaging agent Illuccix, turned Telix from a clinical-stage story into a commercial radiopharmaceutical business with real, fast-compounding revenue and a global supply chain for short-lived medical isotopes that is genuinely hard to replicate.

What is TLX's share price doing?

Snapshot

Share price activity
Last price
A$16.30
52 week range
A$8.63 – A$17.85
Position in range
83%
Daily turnover, 10d avg
0.52%
Beta
1.21
Performance
1 week
-0.6%
1 month
-3.4%
3 months
-1.6%
6 months
+6.6%
1 year
+9.9%
3 years
+51.6%
5 years
+155.8%
Since listing
21×
Price return, dividends excluded.
Key fundamentals
P/E
111.68x
P/E forward
522.99x
PEG
n/a
Price to book
7.68x
Dividend yield
0.00%
Return on equity
-1.85%
Net margin
-0.89%
Debt to equity
112.5%
Last full financial year.
Size
Market cap
A$5.37bn
Net debt
US$325
Revenue
US$804
Total assets
US$1.16k
Shares on issue
340.33m
Size band
Large cap
JDS rank, global
#35,513 of 52,149
Consensus
Analysts covering
15
Consensus rating
Locked
Consensus target
Locked
Implied vs last
Locked
Broker consensus collected by our data vendor. Not our rating.

Latest announcements

04 Oct 2026 Notification of cessation of securities - TLX 04 Oct 2026 Notification regarding unquoted securities - TLX 04 Oct 2026 Application for quotation of securities - TLX 29 Sep 2026 FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging Price sensitive

Company details

Listing
Listed on
Australian Securities Exchange
Ticker
TLX
ISIN
AU000000TLX2
Listing date
15 Nov 2017
Sector
Health Care
Industry
Biotechnology
Index membership
S&P/ASX 300, S&P/ASX 200, S&P/ASX 200 Health Care (Sector), S&P/ASX MID CAP 50
Employees
1,120
Contact and registry
Website
telixpharma.com

Insiders

Board and management
Mr David Gill Non-executive Chair
Dr Christian Behrenbruch Managing Director
Mr William Jellison Non-executive Director
Ms Marie McDonald Non-executive Director
Dr Mark Nelson Non-executive Director
Dr Maria Rivas Non-executive Director
Ms Jann Skinner Non-executive Director
Mr Darren Smith Chief Financial Officer
Mr Shomalin Naidoo Company Secretary
Names and titles as published by the exchange.
Director interests and substantial holdings
25 Sep 2026 Change in substantial holding 25 Sep 2026 Appendix 3Y Change in Director Interest-D Gill 23 Jul 2026 Change in substantial holding 08 Jul 2026 Change in substantial holding 03 Jul 2026 Ceasing to be a substantial holder 01 Jul 2026 Change in substantial holding 30 Jun 2026 Change in substantial holding 30 Jun 2026 Becoming a substantial holder 24 Jun 2026 Becoming a substantial holder 23 Jun 2026 Ceasing to be a substantial holder
Each notice is the filing itself. The shareholdings and the dealings are stated inside the document, which we link rather than transcribe.

How does Telix Pharmaceuticals Limited score on Alpha360?

The eight tabs below are the Alpha360 factor scores. Built on decades of academic research, Alpha360 grades Telix Pharmaceuticals Limited from 0 to 100 on each dimension against all listed stocks worldwide, so a reading in the 90s is genuinely top-tier rather than a pass mark, and the Jones Dynamic Risk Score blends all eight into a single number. Each tab gives the score, a read of what it looks like in practice, and the numbers beneath it. General information only.

Rank by Jones Dynamic Risk Score
Sector 10 of 13
Country (AU) 1,171 of 1,794
Global 35,513 of 52,149
Financial history FY21 to FY25, reported in AUD
Pre-2023 members only
Revenue A$803.8m
FY17 FY25
Net income (A$7.1m)
FY17 FY25
  FY25 Dec 2025 FY24 Dec 2024 FY23 Dec 2023 FY22 Dec 2022 FY21 Dec 2021
Profitability
NPAT (A$7.1m) A$33.7m A$4.2m
NPAT margin -0.9% 6.5% 1.3%
Revenue A$803.8m A$516.6m A$333.0m
Return on equity -1.1% 13.9% 18.1%
Return on assets -0.7% 5.2% 6.4%
Return on capital 3.8% 19.4% –
Valuation
P / E 233.08x 149.79x –
Price / book 5.99x 18.90x 43.13x
EV / EBITDA 62.39x 93.63x –
Market cap A$3.79bn A$8.24bn A$3.26bn
Enterprise value A$2.74bn A$5.03bn A$2.14bn
Shares outstanding 338.76m 334.72m 323.73m
Price / sales 3.79x 12.04x 9.25x
EV / sales 4.11x 11.88x 8.92x
Growth & efficiency
Revenue growth 55.6% 55.1% 200.0%
EPS growth -121.6% 650.6% 105.6%
Operating margin 3.7% 10.7% 3.3%
EBITDA margin 6.5% 11.6% 5.0%
Asset turnover 0.76 0.85 1.48
Effective tax rate – 11.2% -62.2%
Per share
Earnings per share A$-0.02 A$0.10 A$0.01
Dividend per share A$0.00 – –
Free cash flow / sh A$-0.12 A$0.02 A$0.00
Book value / share A$1.23 A$1.07 A$0.32
Payout ratio – 0.0% 0.0%
  FY25 Dec 2025 FY24 Dec 2024 FY23 Dec 2023 FY22 Dec 2022 FY21 Dec 2021
Income statement
Revenue A$803.8m A$516.6m A$333.0m
Cost of goods sold A$421.9m A$197.1m A$129.7m
Gross profit A$381.8m A$319.5m A$203.3m
Gross margin 47.5% 61.9% 61.0%
Operating expenses A$774.0m A$461.4m A$322.0m
Research & development A$171.2m A$127.9m A$85.3m
Selling, general & admin A$192.6m A$129.5m A$83.1m
EBITDA A$52.4m A$60.0m A$16.8m
EBIT A$30.9m A$54.6m A$12.3m
Interest expense A$13.8m A$4.8m A$520.0k
Pretax income (A$5.3m) A$37.9m A$2.6m
Tax A$1.9m A$4.2m (A$1.6m)
Net income (A$7.1m) A$33.7m A$4.2m
EPS basic A$-0.02 A$0.10 A$0.01
EPS diluted A$-0.02 A$0.10 A$0.01
  FY25 Dec 2025 FY24 Dec 2024 FY23 Dec 2023 FY22 Dec 2022 FY21 Dec 2021
Assets
Cash & equivalents A$141.9m A$440.0m A$84.3m
Receivables A$138.4m A$99.7m A$49.3m
Inventory A$37.1m A$23.6m A$12.7m
Current assets A$330.3m A$570.1m A$158.7m
Property, plant & eq A$115.6m A$33.6m A$20.9m
Goodwill A$199.0m A$66.6m –
Intangibles A$393.8m A$191.3m A$75.1m
Total assets A$1.16bn A$940.4m A$277.3m
Liabilities & equity
Accounts payable A$71.7m A$42.2m –
Short term debt A$0 A$0 A$0
Current liabilities A$231.6m A$205.1m A$111.4m
Long term debt A$448.4m A$346.9m A$11.2m
Total liabilities A$748.6m A$587.4m A$174.6m
Total debt A$467.1m A$360.2m A$12.3m
Net debt A$325.2m (A$79.8m) (A$72.0m)
Total equity A$415.4m A$352.9m A$102.6m
Working capital A$98.7m A$365.0m A$47.3m
Debt to equity 112.45 102.05 11.95
Current ratio 1.43 2.78 1.42
Quick ratio 1.27 2.66 1.31
Interest coverage 3.64 – 43.28
Retained earnings (A$52.1m) (A$55.6m) (A$204.7m)
Tangible book value (A$147.8m) – –
  FY25 Dec 2025 FY24 Dec 2024 FY23 Dec 2023 FY22 Dec 2022 FY21 Dec 2021
Cash flow
Operating cash flow (A$17.3m) A$27.5m A$14.3m
Share-based comp A$19.1m A$13.0m –
Change in working cap (A$45.9m) (A$16.7m) (A$9.8m)
Capital expenditure (A$56.0m) (A$30.6m) (A$7.1m)
Free cash flow (A$41.6m) A$8.5m A$1.6m
Investing cash flow (A$285.9m) (A$86.7m) (A$16.8m)
Debt issued A$529.0k A$427.9m A$4.2m
Debt repaid (A$6.1m) (A$2.1m) (A$1.3m)
Financing cash flow (A$3.7m) A$416.8m A$7.1m
Net change in cash (A$298.1m) A$355.7m A$5.5m
  FY25 Dec 2025 FY24 Dec 2024 FY23 Dec 2023 FY22 Dec 2022 FY21 Dec 2021
Dividend
Dividend per share A$0.00 – –
Payout ratio – 0.0% 0.0%
Cover and capacity
Earnings per share A$-0.02 A$0.10 A$0.01
Free cash flow / sh A$-0.12 A$0.02 A$0.00
Free cash flow (A$41.6m) A$8.5m A$1.6m
Other capital returns
Shares outstanding 338.76m 334.72m 323.73m
History before 2023 is members only Become a member
The method

Every score on this page comes from Alpha360, the eight-factor model built by Professor Stewart Jones from three decades of published academic research, rescored weekly across more than 50,000 listed companies worldwide.

The research behind Alpha360 → Understand the scores → How Alpha360 works →

Filings & Announcements

Our call

What we rate Telix Pharmaceuticals Limited

Current rating Locked
  • Buy, hold or sell
  • The Alpha360 score and all eight factors
  • Our Top 3 Buys report
  • Free 15-minute walkthrough
Confirm your email for 3 free scorecards of your choice. Members see every company.
Questions

Common questions about TLX

What is Telix Pharmaceuticals Limited's Jones Dynamic Risk Score?
Telix Pharmaceuticals Limited currently scores 24.7 (Very Weak) on the Jones Dynamic Risk Score. The score is recalculated weekly from institutional-grade data.
Is TLX profitable?
Not at the net line on the latest data: Telix Pharmaceuticals Limited reports a net profit margin of -0.9%.
How does TLX compare to its peers?
Ranked by the Jones Dynamic Risk Score, Telix Pharmaceuticals Limited sits 10 of 13 in its Health Care peer group. The full peer ranking, with each peer's score, is shown on this page.
Is this personal financial advice?
No. Everything on this page is general information only. It does not take into account your objectives, financial situation or needs, and you should consider whether it is appropriate for you before acting on it. The full General Advice Warning is at the bottom of this page.
What does it cost to see your rating on Telix Pharmaceuticals Limited?
Nothing. Enter your details in the form on this page and our current rating unlocks instantly, along with a free one-on-one walkthrough of the research with our team if you want it. The full written research note is part of membership.
Who builds the scores?
The Jones Dynamic Risk Score and the Alpha360 factor model were built in-house from three decades of academic research. The system scores companies across global markets and is refreshed weekly.
Go deeper

Book a free walkthrough

Fifteen minutes, one on one with our research team: how the scores work, what they say about Telix Pharmaceuticals Limited, and what members get. No cost, no obligation.

Book a walkthrough

The full research note

Members get the complete written research note from the Financial Trends Australia analysts. Information only, not personal financial advice, and no performance is promised.

Become a member

Want our call on another stock?

Tell us the ticker or company name and we will point you to our research, or let you know when its page is live.

General Advice Warning. The information provided by Financial Trends Australia is general in nature and does not take into account your personal objectives, financial situation or needs. It does not constitute personal financial advice. Before acting on any information, you should consider its appropriateness having regard to your own objectives, financial situation and needs, and seek independent professional advice. Where the information relates to a financial product, you should obtain and consider the relevant Product Disclosure Statement (PDS) or offer document before deciding to acquire the product. Past performance is not a reliable indicator of future performance. Financial Trends Australia Pty Ltd (ABN 65 091 191 472) is a Corporate Authorised Representative (AR No. 001320926) of MF & Co. Asset Management Pty Ltd (AFSL No. 520442).